Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Eimy Honda"'
Autor:
Allisson Monteiro da Silva, Thais Tiemi Wepeck Oliveira Watanabe, Eimy Honda, Juliana Yamaguchi
Publikováno v:
Journal of Clinical Oncology. 39:e14504-e14504
e14504 Background: In 2017, biosimilar trastuzumab (Zedora) became the first biosimilar trastuzumab approved in Brazil. In May 2018 an active postmarketing surveillance program was instituted. Data from this program was presented in ASCO in 2019 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d1210f828abcea5d8eed02a00e98ab03
https://doi.org/10.1200/jco.2021.39.15_suppl.e14504
https://doi.org/10.1200/jco.2021.39.15_suppl.e14504
Autor:
Eimy Honda, Allisson Monteiro da Silva, Juliana Yamaguchi, Thais Tiemi Wepeck Oliveira Watanabe
Publikováno v:
Journal of Clinical Oncology. 38:e15626-e15626
e15626 Background: In 2017, biosimilar trastuzumab (Zedora) became the first biosimilar trastuzumab approved in Brazil. In 2019, biosimilar trastuzumab early data from an active postmarketing surveillance program were presented in ASCO. Now, with an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce2cea3aa679b54587f478e6179b1823
https://doi.org/10.1200/jco.2020.38.15_suppl.e15626
https://doi.org/10.1200/jco.2020.38.15_suppl.e15626